Minimally invasive surgery by means of a catheter is now a part of everyday life in hospitals. However, the position of the catheter has to be checked using a contrast dye and x-ray, which can lead to health complications in many patients. Up to 41 per cent of patients are at risk of developing kidney damage or allergic reactions to the dye.
The catheter positioning system developed by Medyria does away with x-rays and contrast dyes, which significantly reduces the risk of complications and in turn shortens hospital stays. This is accomplished by means of a sensor technology for measuring blood flow and a software.
Medyria has now closed a series B financing round in the amount of 3.7 million Swiss francs, 1.3 million of which comes from investiere.ch. According to a statement, the investment platform has “always believed” in the potential of Medyria’s technology, and already in 2014 conducted a first investment round in the company and added it to its portfolio.
In addition to its successful financing round, Medyria has achieved a further milestone: the German Federal Institute for Drugs and Medical Devices (BfArM) has given the startup the green light to conduct its first-in-human clinical trials.
“We are very happy and proud that we could enable our investors to participate in two financing rounds before the first human trials,” said Michael Blank, investment manager at investiere.ch.
Founded in 2014, Medyria is located in the Greater Zurich Area.